AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 32705833
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group received intravenous injection of Tropisetron (5 mg) 1 h before chemotherapy
Trial: 36721509
Drug: Levofloxacin 750
RxNorm normalized name: levofloxacin 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levofloxacin 750 mg daily for five days
Trial: 36721509
Drug: Ceftriaxone 1
RxNorm normalized name: ceftriaxone 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone 1 gram daily and azithromycin 500 mg daily for 5-7 days
Trial: 36444879
Drug: Basic body
RxNorm normalized name: Basic Fuchsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basic body awareness therapy (BBAT) 3 days a week for 6 weeks in addition to a home-based exercise programme
Trial: 32353635
Drug: Decision‐Rule Based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decision‐Rule Based Treatment (DR)
Trial: 32353635
Drug: Sequential Treatment
RxNorm normalized name: TABLET, SEQUENTIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential Treatment (SEQ)
Trial: 32275367
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment (electroacupuncture at specified acupoints, continuous wave, 2 Hz, 30 min, 3 times a week for 1 month, 4 courses total)
Trial: 33245796
Drug: Evogliptin (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evogliptin (5 mg single dose) in patients with mild hepatic impairment
Trial: 33245796
Drug: Evogliptin (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evogliptin (5 mg single dose) in patients with moderate hepatic impairment
Trial: 33245796
Drug: Evogliptin (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evogliptin (5 mg single dose)
Trial: 32714084
Drug: Intermittent repeated
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent repeated doses of dexamethasone (15 mg total)
Trial: 32714084
Drug: One-time 5-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One-time 5-mg dose of dexamethasone
Trial: 35941548
Drug: Transforaminal injection
RxNorm normalized name: transforming growth factor beta 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transforaminal injection of Magnesium sulphate with steroids
Trial: 35941548
Drug: Transforaminal injection
RxNorm normalized name: transforming growth factor beta 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transforaminal injection of Ozone with steroids
Trial: 33226116
Drug: Inverse probability
RxNorm normalized name: Inversedine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inverse probability of treatment weights (IPTWs)
Trial: 32023373
Drug: Lower threshold
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower threshold treatment (glucose concentration <36 mg/dL)
Trial: 34719909
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment with portable magnet therapy device ALMAG+ (Almag Active)
Trial: 36350354
Drug: Model-informed precision
RxNorm normalized name: INFORMATION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Model-informed precision dosing (MIPD) of beta-lactam antibiotics and ciprofloxacin
Trial: 36350354
Drug: Standard dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dosing of beta-lactam antibiotics and ciprofloxacin
Trial: 36795232
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylphenidate (MPH) treatment
Trial: 35143022
Drug: Baseline comorbidities
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline comorbidities and treatments
Trial: 35143022
Drug: Drugs increasing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drugs increasing risk
Trial: 37261907
Drug: Repository corticotropin
RxNorm normalized name: Repository Corticotropin Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repository corticotropin injection (RCI)
Trial: 32357128
Drug: Telerehabilitation-based McKenzie
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telerehabilitation-based McKenzie therapy (TBMT)
Trial: 32357128
Drug: Clinic-based McKenzie
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinic-based McKenzie therapy (CBMT)
Trial: 33591324
Drug: RW-CHOP (CHOP-21
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RW-CHOP (CHOP-21 with 8 doses of weekly rituximab [375 mg/m2])
Trial: 33591324
Drug: R-CHOP (CHOP-21
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R-CHOP (CHOP-21 with 8 doses of rituximab once every 3 weeks [375 mg/m2])
Trial: 33034180
Drug: Vacuum-gradient therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vacuum-gradient therapy combined with orthodontic correction (n=29)
Trial: 36071424
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care treatment
Trial: 37500339
Drug: Atezolizumab (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atezolizumab (1200 mg every 3 weeks)
Trial: 34326048
Drug: 0.05% potassium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05% potassium permanganate (KMnO4) solution
Trial: 34326048
Drug: 5% tea
RxNorm normalized name: IODINE 5 g in 1 L TOPICAL SOLUTION [DariSoft .5% Teat Dip]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% tea tree oil (TTO) gel
Trial: 33122343
Drug: Neoadjuvant anti-HER2
RxNorm normalized name: anti-CD11a
DrugBank: Efalizumab (DB00095)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Neoadjuvant anti-HER2 therapy
Trial: 35140313
Drug: 4000 IU
RxNorm normalized name: Cholecalciferol 4000 IU Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4000 IU of vitamin D3 taken daily
Trial: 35064366
Drug: Ibuprofen (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (400 mg) at 8 AM, 1 PM, and placebo at 8 PM
Trial: 35064366
Drug: Ibuprofen (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (400 mg) at 8 AM, 1 PM, and 8 PM (Control)
Trial: 34542190
Drug: Antioxidants and
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidants and zinc combination
Trial: 38952884
Drug: Placebo (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (2 doses)
Trial: 37919141
Drug: mRNA-1273 (Spikevax®,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mRNA-1273 (Spikevax®, 100 µg)
Trial: 36016478
Drug: Local ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Local ibuprofen (Odontocide)
Trial: 36016478
Drug: Systemic ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Systemic ibuprofen (Ultracal + 200 mg ibuprofen)
Trial: 36164019
Drug: P1101 (ropeginterferon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P1101 (ropeginterferon Alfa-2b) administered subcutaneously every 2 weeks at starting dose of 250 mcg (Week 0), 350 mcg (Week 2), and target dose of 500 mcg (Week 4) for the remainder of the treatment period.
Trial: 36348617
Drug: Clade C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clade C regimen (adenovirus 26-based HIV-1 vaccine encoding 2 mosaic Gag and Pol, and 2 mosaic Env proteins plus adjuvanted clade C gp140)
Trial: 35013548
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care medical treatment
Trial: 36307956
Drug: Moderate-protein diet
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate-protein diet with 25 g beef/d (B25, n=45)
Trial: 35120546
Drug: Conventional physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional physical therapy program
Trial: 33602603
Drug: Biotène Moisturizing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biotène Moisturizing Spray (3 sprays)
Trial: 34310874
Drug: Electrochemotherapy (ECT)
RxNorm normalized name: ECT-001 expanded cord blood
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electrochemotherapy (ECT) with intravenous and intratumoral administration of bleomycin
Trial: 33027362
Drug: Cefazolin (antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefazolin (antibiotic group)
Trial: 35822425
Drug: ACE inhibitor
RxNorm normalized name: ACE INHIBITORS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE inhibitor (ACEi)
Trial: 34495579
Drug: 5 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 g of fresh table grape per kg of body weight for 21 days
Trial: 33720637
Drug: Donanemab (700
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donanemab (700 mg for the first three doses and 1400 mg thereafter)
Trial: 35241182
Drug: General form
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General form of CBT treatment
Trial: 36453313
Drug: Subconjunctival MMC
RxNorm normalized name: MMC
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subconjunctival MMC injection at the end of trabeculectomy
Trial: 36453313
Drug: IntraTenon MMC
RxNorm normalized name: MMC
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IntraTenon MMC injection before the initial conjunctival incision
Trial: 34624174
Drug: FDC tablets
RxNorm normalized name: DYE FDC BLUE #1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FDC tablets of macitentan/tadalafil (10/40 mg)
Trial: 35151971
Drug: Amitriptyline (AMT)
DrugBank: Amitriptyline (DB00321)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amitriptyline (AMT) 25 mg every night
Trial: 33630912
Drug: Retina fraction
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retina fraction dose
Trial: 35665493
Drug: Distraction therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Distraction therapy
Trial: 33017120
Drug: Control (placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (placebo treatment)
Trial: 34862248
Drug: Pembrolizumab monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab monotherapy (200 mg IV every 3 weeks)
Trial: 34862248
Drug: Pembrolizumab +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab + Acalabrutinib (100 mg orally twice daily)
Trial: 34592684
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg methylphenidate (N=13)
Trial: 34592684
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg caffeine (N=14)
Trial: 36134902
Drug: Denosumab (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Denosumab (60 mg subcutaneously q6 months)
Trial: 34322673
Drug: Rifaximin 550
RxNorm normalized name: rifAXIMin 550 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifaximin 550 mg BID for 10 days
Trial: 34903538
Drug: Chlorhexidine oral
RxNorm normalized name: chlorhexidine Oral Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorhexidine oral rinses (0.12%)
Trial: 36167367
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of intravenous iron and tranexamic acid
Trial: 32609576
Drug: All groups
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All groups (C, L, L + P)
Trial: 33507774
Drug: ACCESS (cognitive-behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACCESS (cognitive-behavioral therapy program)
Trial: 32726556
Drug: Multiple punctures
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple punctures injection technique of incobotulinumtoxin A (IncoA; Xeomin)
Trial: 32726556
Drug: Radial injection
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radial injection technique of incobotulinumtoxin A (IncoA; Xeomin)
Trial: 35454318
Drug: Repeated injection
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated injection of 2 mL of 1% lidocaine (three injections; one injection per week)
Trial: 35454318
Drug: Radial extracorporeal
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radial extracorporeal shock wave therapy (rESWT) (three treatment sessions; one treatment session per week; 2000 radial extracorporeal shock waves per treatment session; positive energy flux density = 0.10 mJ/mm2)
Trial: 36490292
Drug: Cognitive Behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioural Therapy (CBT) intervention, average of 12 sessions
Trial: 36490292
Drug: Cognitive Behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioural Therapy (CBT) intervention
Trial: 34645660
Drug: Ibuprofen and
RxNorm normalized name: Ibuprofen and Famotidine Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen and short intervention
Trial: 35916290
Drug: Secukinumab 300mg
RxNorm normalized name: Secukinumab
DrugBank: Secukinumab (DB09029)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Secukinumab 300mg with loading dose
Trial: 35916290
Drug: Secukinumab 150mg
RxNorm normalized name: SECUKINUMAB 150MG/ML INJ,SYR,1ML
DrugBank: Secukinumab (DB09029)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Secukinumab 150mg without loading dose
Trial: 32465000
Drug: Riociguat (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Riociguat (up to 2.5 mg tid)
Trial: 33615843
Drug: Unblinded nitroglycerin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unblinded nitroglycerin infusion at 0.5 µg/kg/min for 20 minutes
Trial: 33615843
Drug: Unblinded nitroglycerin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unblinded nitroglycerin infusion
Trial: 33615843
Drug: Single-blinded nitroglycerin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-blinded nitroglycerin infusion
Trial: 33615843
Drug: Single-blinded placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-blinded placebo infusion
Trial: 33933059
Drug: Vitamin K2
RxNorm normalized name: Vitamin K2
DrugBank: Menaquinone 6 (DB14936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin K2 (360 μg MK-7 daily for 12 weeks)
Trial: 32118347
Drug: Patient-managed (nurse-assisted)
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-managed (nurse-assisted) titration of Gla-300
Trial: 34420049
Drug: Dispersible paediatric
RxNorm normalized name: Disperse Blue 106
DrugBank: Disperse Blue 106 (DB14203)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dispersible paediatric fixed dose combination (FDC) tablets delivering higher doses of first‐line antituberculosis drugs (rifampicin/isoniazid/pyrazinamide 75/50/150 mg, with or without 100 mg ethambutol, or rifampicin/isoniazid 75/50 mg)
Trial: 34420049
Drug: Recommended weight-band
RxNorm normalized name: Band-Aid Hurt-Free
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recommended weight-band based FDC doses
Trial: 34420049
Drug: Ethambutol at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethambutol at current WHO-recommended doses
Trial: 33906450
Drug: Radial extracorporeal
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radial extracorporeal shock wave therapy
Trial: 34551215
Drug: iGlarLixi +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iGlarLixi + insulin glulisine
Trial: 33040383
Drug: Multiple daily
RxNorm normalized name: Multivitamin Oral Tablet [MULTIPLE DAILY W/BETA]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple daily injection therapy
Trial: 34619438
Drug: ND0612 (levodopa/carbidopa)
RxNorm normalized name: carbidopa / levodopa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ND0612 (levodopa/carbidopa) infusion
Trial: 34619438
Drug: Placebo infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo infusion + standard of care (SoC)
Trial: 35550468
Drug: Sinomenine (zhengqing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sinomenine (zhengqing fengtongning sustained-release tablets) administered for 12 weeks.
Trial: 35550468
Drug: Colchicine placebo
RxNorm normalized name: Colchicine
DrugBank: Colchicine (DB01394)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Colchicine placebo administered for 12 weeks along with febuxostat (40 mg/d) and anti-inflammatory prophylaxis therapy.
Trial: 35550468
Drug: Colchicine administered
RxNorm normalized name: Colchicine
DrugBank: Colchicine (DB01394)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Colchicine administered for 12 weeks.
Trial: 32966919
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D supplementation (300 IU/kg up to a maximum of 6000 IU daily)
Trial: 36305511
Drug: Scheduled acetaminophen,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scheduled acetaminophen, gabapentin, ketorolac, and as-needed opioids (Experimental group)
Trial: 36305511
Drug: Scheduled acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scheduled acetaminophen and as-needed opioids (Control group)
Trial: 34538072
Drug: Adavosertib (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adavosertib (250 mg or 300 mg)
Trial: 35439303
Drug: Rivaroxaban 15
RxNorm normalized name: rivaroxaban 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban 15 mg twice daily for 3 weeks, followed by 20 mg daily for an intended duration of 3 months
Trial: 33234138
Drug: Estradiol therapy
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Estradiol therapy for women > 50 years
Trial: 33234138
Drug: No estradiol
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No estradiol therapy for women > 50 years
Trial: 33026490
Drug: Yoga therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yoga therapy (8 weekly sessions of 60 min each)
Trial: 36417955
Drug: Liberal transfusion
RxNorm normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liberal transfusion strategy (transfusion of RBCs sufficient to raise hemoglobin to at least 10 g/dL)
Trial: 36417955
Drug: Restrictive transfusion
RxNorm normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restrictive transfusion strategy (transfusion of RBCs if hemoglobin falls below 8 g/dL or for persistent angina despite medical therapy)
Trial: 33430476
Drug: Ai Chi
RxNorm normalized name: BUTYLENE GLYCOL 48 g in 240 mL CUTANEOUS TAPE [QIZHOUGUAI Chinese medicine patch]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ai Chi aquatic therapy
Trial: 32630188
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy (alternating dry-land therapy and Ai Chi aquatic therapy)
Trial: 32630188
Drug: Dry-land therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dry-land therapy (control group)
Trial: 33023894
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment with sodium nitrite (40 mg twice daily) and isoquercetin (225 mg once daily) for 12 weeks
Trial: 33023894
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment with sodium nitrite and isoquercetin
Trial: 33109661
Drug: Nebuliser with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebuliser with data recording and transfer capability, linked to a software platform, and strategies to support adherence to nebulised treatments facilitated by interventionists over 5 months (+/‐ 1 month)
Trial: 32487250
Drug: PST-IPV (Problem
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PST-IPV (Problem Solving Therapy tailored for IPV)
Trial: 32487250
Drug: Standard PST
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard PST (Problem Solving Therapy)
Trial: 35277034
Drug: Caffeine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (3 mg/kg body mass)
Trial: 35141484
Drug: Radial extracorporeal
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radial extracorporeal shock wave therapy (rESWT) - 25 patients, 3 sessions (once per week, 1.8 bar pneumatic pressure, 10 Hz frequency, 2,000 pulses)
Trial: 38103144
Drug: Occupational therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Occupational therapy
Trial: 36351465
Drug: Rosuvastatin 5
RxNorm normalized name: rosuvastatin 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin 5 mg daily
Trial: 35307033
Drug: Ezetimibe 10
RxNorm normalized name: ezetimibe 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezetimibe 10 mg plus rosuvastatin 5 mg daily
Trial: 38796500
Drug: Oral antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral antibiotics
Trial: 32782010
Drug: 5 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 g/day thylakoid
Trial: 32986105
Drug: Targeted gene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Targeted gene testing (TGT) and tailored first-line therapy
Trial: 32986105
Drug: Empirical imatinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empirical imatinib therapy